NovaQuest Capital Management's 13F Holdings: A Look into Q2-Q3 Changes

As an investor, keeping track of the changes in the holdings of your favored fund can help you get ahead of the curve. NovaQuest Capital Management, L.L.C. recently released their Q2 2020-Q3 2020 13F holdings comparison summary, which will give you an idea of the changes in their portfolio. This summary highlights the changes in the shares and values of two of their main investment options – MYOVANT SCIENCES LTD. (MYOV) and REVANCE THERAPEUTICS, INC. (RVNC).

MYOVANT SCIENCES LTD.—Steady Growth in Shares with a Sharp Decline in Value

MYOV is a healthcare product company that focuses on women's health and prostate cancer. It is one of NovaQuest Capital Management's major investment options and has remained consistent in terms of shareholding. In the Q2 2020 13F holdings, the fund had 3,474,645 shares with a value of $71,647,000. This figure has remained the same in Q3 2020. However, the value decreased by 31.9% to $48,819,000.

MYOV has been on a steady uphill trajectory this year. The company announced positive results from their phase 3 clinical trial of ORGOVYX (relugolix) for prostate cancer treatment, leading to a surge in share prices. Although the value decreased in Q3 2020, it does not necessarily represent the future of the company's share price.

REVANCE THERAPEUTICS, INC. - A Significant Decline in Both Shares and Value

RVNC is another healthcare product company that specializes in aesthetic and therapeutic offerings. NovaQuest Capital Management had 598,985 shares with a value of $14,627,000 in Q2 2020. However, the value declined by 62.9% to $5,431,000 in Q3 2020, with the number of shares decreasing significantly to 216,038.

The decline in value could be related to the recent shelf offering of shares by the company, which allows them to raise capital to fund their business operations. However, the significant reduction in shares implies that the fund is losing its faith in the company's future performance.

Conclusion

NovaQuest Capital Management's latest summary provides insights into the changes in the holdings of MYOV and RVNC investment options. MYOV has been consistent in terms of shareholding but experienced a decline in value. Whereas, RVNC experienced a significant decline in both shares and value. It is essential to note that the summary only represents a snapshot of the fund's investments and may not provide a comprehensive picture of their overall portfolio. As such, it is advisable to consider other factors before making investment decisions.